The money is Indiana’s share in the $181 million settlement over Janssen Pharmaceutical’s drug, Risperdal. The case marks the largest consumer protection-based pharmaceutical settlement ever reached, the Indiana Attorney General’s Office said.
Federal law prohibits drug manufacturers from promoting their products for such “off-label” uses, even though doctors can prescribe the drug for those uses.
“As part of being the watchdog for consumers, it is the Attorney General’s responsibility to ensure pharmaceutical companies are not marketing drugs for unapproved uses to boost sales,” said Indiana Attorney General Greg Zoeller. “Today’s multistate agreement should send a strong message that off-label marketing is illegal and will not be tolerated.”
After an extensive investigation, Janssen agreed to change how it promotes its products and agreed to refrain from misleading or deceptive promotion of the drugs.
The Attorneys General of the following states took part in the settlement: Alabama, Arizona, Colorado, Connecticut, Delaware, Florida, Hawaii, Idaho, Illinois, Indiana, Iowa, Kansas, Maine, Maryland, Michigan, Minnesota, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, South Dakota, Tennessee, Texas, Vermont, Washington, Wisconsin and Wyoming.